AbbVie introduces Produodopa for advanced Parkinson’s in EU
The treatment is indicated for use in PD patients experiencing severe motor fluctuations and hyperkinesia or dyskinesia. This marks the introduction of the first 24-hour continuous subcutaneous infusion